Following POLITICO Pro’s publication of the Commission’s Pharmaceutical Legislation Impact Assessment the future of Europe’s life sciences sector remains in sharp focus.
From the outset of this Commission, President von der Leyen’s aims — to ensure Europe has the supply of affordable medicines to meet its needs, and to support the European pharmaceutical industry to ensure that it remains an innovator and world leader — gave some hope to an industry in Europe that’s seeing investment leave its shores for Asia and the U.S.
Many people are unaware of the essential role that Intellectual Property (IP) played in the response to COVID-19.
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.